Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth

Area of Science:

• Biotechnology
• Molecular Biology
• Nanomedicine

Background:

• Short interfering RNA (siRNA) offers therapeutic potential for gene-specific disorders.
• Poor cellular uptake and bioavailability limit in vivo siRNA applications.
• Existing delivery strategies often fall short for clinical use.

Purpose of the Study:

• To develop a novel peptide-based delivery system for enhanced siRNA cellular uptake and in vivo bioavailability.
• To improve the therapeutic efficacy of siRNA for cancer treatment.
• To evaluate the safety and stability of the developed delivery system.

Main Methods:

• Development of MPG-8, a peptide carrier derived from MPG, for siRNA complexation.
• Formation of nanoparticles for efficient siRNA delivery into primary cell lines.
• In vivo studies involving intra-tumoral and intravenous administration in mouse tumor models.
• Cholesterol functionalization of MPG-8 to enhance tissue distribution and stability.

Main Results:

• MPG-8 efficiently formed nanoparticles with siRNA, promoting cellular uptake.
• Cholesterol-functionalized MPG-8 significantly improved in vivo siRNA tissue distribution and stability.
• Systemic administration via intravenous injection showed enhanced efficacy without inflammatory responses.
• Targeting cyclin B1 in mouse models demonstrated compromised tumor growth, validating therapeutic potential.

Conclusions:

• MPG-8 represents a promising peptide-based technology for efficient siRNA delivery.
• Cholesterol functionalization enhances the in vivo performance of siRNA therapeutics.
• This approach holds significant promise for systemic siRNA administration in cancer treatment.